Healthy Food Evaluation Research Center, West China School of Public Health and West China Fourth Hospital, Sichuan University, 16 Renminnan Road 3rd Section, Chengdu, 610041, Sichuan, China.
Pharm Res. 2020 Mar 25;37(4):72. doi: 10.1007/s11095-020-02791-2.
Combination of PCI and chemotherapy represents a promising strategy for combating drug resistance of cancer. However, poor solubility of photosensitizers and unselectively released drugs at unwanted sites significantly impaired the treatment efficacy. Therefore, in the present study, we aimed to develop a nano-platform which could efficiently co-entrapping photosensitizers and chemotherapeutics for active targeting therapy of drug resistant cancers.
Two pro-drugs were respectively developed by covalently linking the Ce6 with each other via the GSH-sensitive linkage and the PTX with mPEG-PLA-COOH through the ROS sensitive-linker. The dual-responsive nanoparticles (PNP-Ce6) was developed by emulsion/solvent evaporation method and further modified with tLyp-1 peptides. Physicochemical properties of nanoparticles were determined by the TEM and DLC. Cellular uptake assay was investigated with the Ce6 acting as the fluorescent probe and cell growth was studied by the MTT experiment. In vivo tumor targeting and anti-tumor assay was investigated on the colorectal cancer-bearing mice.
The developed tPNP-Ce6 were stable enough under the normal physiological conditions. However, free Ce6 and PTX were completely released when exposed the tPNP-Ce6 to the redox environment. Excellent tumor-targeting drug delivery was achieved by the tPNP-Ce6, which in turn resulted in satisfactory anit-tumor effect. Of great importance, super inhibition effect on tumor progress was achieved by the combination therapy when compared with the group only received with chemotherapy..
The results obtained in the present study indicated that the developed tPNP-Ce6 may have great potential in enhancing the therapeutic efficacy of drug-resistant colorectal cancer. Graphical Abstract Left: Targeting delivery of drug to tumor site by the tumor recognizable and dual-responsive nanoparticles and penetrating into tumor inner via the mediation of irradiation. Right: Nanoparticle distribution within tumor tissues with green represents the blood vessels stained with CD31, blue signal represents the cell nuclei stained with DAPI and red shows fluorescence of Ce6 as the indicator of the nanoparticles.
经皮冠状动脉介入治疗(PCI)联合化疗代表了一种有前途的策略,可用于对抗癌症的耐药性。然而,光敏剂的溶解度差以及在不需要的部位非选择性释放药物,极大地影响了治疗效果。因此,在本研究中,我们旨在开发一种纳米平台,该平台能够有效地共包封光敏剂和化疗药物,用于耐药性癌症的主动靶向治疗。
通过将 GSH 敏感键连接在一起,将 Ce6 与彼此共价连接,将 PTX 通过 ROS 敏感键连接到 mPEG-PLA-COOH 上,分别制备了两种前药。通过乳液/溶剂蒸发法制备了双响应性纳米颗粒(PNP-Ce6),并进一步用 tLyp-1 肽进行修饰。通过 TEM 和 DLC 测定了纳米颗粒的物理化学性质。用 Ce6 作为荧光探针进行细胞摄取实验,用 MTT 实验研究细胞生长情况。在结直肠癌荷瘤小鼠中进行体内肿瘤靶向和抗肿瘤实验。
所开发的 tPNP-Ce6 在正常生理条件下足够稳定。然而,当将 tPNP-Ce6 暴露于氧化还原环境时,游离的 Ce6 和 PTX 则完全释放。tPNP-Ce6 实现了优异的肿瘤靶向药物传递,进而产生了令人满意的抗肿瘤效果。重要的是,与仅接受化疗的组相比,联合治疗对肿瘤进展具有超强的抑制作用。
本研究结果表明,所开发的 tPNP-Ce6 可能具有增强耐药结直肠癌治疗效果的巨大潜力。
图表摘要 左:通过肿瘤识别和双响应性纳米颗粒将药物靶向递送至肿瘤部位,并通过辐射介导穿透肿瘤内部。右:纳米颗粒在肿瘤组织内的分布,绿色表示用 CD31 染色的血管,蓝色信号表示用 DAPI 染色的细胞核,红色显示 Ce6 的荧光作为纳米颗粒的指示剂。